Pancreatic Cancer Program

The radiation/chemotherapy sensitization action of TSC is driven by the presence of tumor hypoxia, rather than a specific tumor type, and pancreatic cancer is widely regarded as one of the most hypoxic cancerous tumors. Therefore, based on preclinical studies and the safety and efficacy observed in the Phase 1/2 TSC GBM study, the Company has been interacting with the USFDA regarding design of a clinical development program testing the use of TSC in pancreatic cancer patients receiving radiation, chemotherapy, or a combination or both.

Because of the safety history of TSC to date, Diffusion should be able to move directly into Phase 2 trials for this indication.